DEMEGEN INC has a total of 17 patent applications. Its first patent ever was published in 1995. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and machines are ALLOGENE THERAPEUTICS INC, ARMEL SA and VOR BIOPHARMA INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 9 | |
#2 | Australia | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Argentina | 1 | |
#6 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Machines |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Microorganisms | |
#4 | Therapeutic chemical compounds | |
#5 | Unspecified technologies |
# | Name | Total Patents |
---|---|---|
#1 | Jaynes Jesse M | 10 |
#2 | Julian Gordon R | 3 |
#3 | Jaynes Jesse | 3 |
#4 | Rothstein David M | 2 |
#5 | Friden Phillip M | 2 |
#6 | Spacciapoli Peter | 2 |
#7 | Friden Philip M | 1 |
#8 | Garbarino Joan | 1 |
#9 | Belknap William | 1 |
#10 | Bromberg Lev | 1 |
Publication | Filing date | Title |
---|---|---|
WO0191553A1 | Composite wafer for controlled drug delivery | |
WO9955890A1 | A method for increasing the protein content of plants | |
US6528488B2 | Method for treating cystic fibrosis | |
AU4602897A | Method for treatment of immunodeficiency virus infection | |
US5955573A | Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same | |
US5968904A | Modified arginine containing lytic peptides and method of making the same by glyoxylation |